Adicet Bio (NASDAQ:ACET) outlined its near-term clinical priorities and upcoming data catalysts during a fireside chat at the Jefferies Healthcare Conference in New York, with President and CEO Chen Schor emphasizing the company’s focus on off-the-shelf gamma delta 1 T-cell therapies for autoimmune disease and oncology.
Schor said Adicet’s platform is designed around gamma delta 1 T cells, which he described as having potential advantages over conventional alpha beta T-cell approaches. He said the cells can be administered allogeneically without gene editing and without the need for leukapheresis, which he characterized as a bottleneck limiting cell therapy availability to a small number of specialized centers.
